Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to 177Lu-PSMA-617
Related studies linked through entity extraction aliases.
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
- Status
- TERMINATED
- Phase
- PHASE2